• Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system

 Aminex Therapeutics, Inc., a private clinical-stage biotechnology company focused on developing novel therapies for rare and difficult-to-treat cancers, today announced the initiation of a Phase 1b/2 clinical trial of AMXT 1501 in combination with difluoromethylornithine (DFMO) in patients with breast cancer or metastatic melanoma.

"Initiating this study is an important milestone for Aminex and for patients facing advanced cancers with limited treatment options," said Mark Burns, PhD, Chief Scientific Officer and President of Aminex. "This trial builds on our foundation of pre- and early clinical data demonstrating the potential of AMXT 1501 plus DFMO to block the polyamine metabolism—a pathway that drives tumor growth and suppresses immune responses. We are advancing this program, in collaboration with leading investigators and pediatric oncologists, targeting eight tumor types."

The multicenter, open-label trial (NCT07287917) will evaluate the safety, tolerability and preliminary efficacy of oral AMXT 1501 in combination with oral DFMO together with standard of care in metastatic melanoma or in pre- and post-menopausal women with ER+ HER2- breast cancer who have progressed after prior therapies. The study will include safety and dose expansion cohorts.

In addition to this trial, Aminex is partnering with The Beat Childhood Cancer Consortium at Penn State College of Medicine on a randomized Phase 1/2 clinical trial of AMXT 1501 plus DFMO in pediatric patients with neuroblastoma, diffuse intrinsic pontine glioma, atypical teratoid rhabdoid tumor, embryonal tumor with multilayer rosettes, ewing sarcoma, and osteosarcoma. (NCT06465199) Aminex also recently announced the receipt of Orphan Drug Designation from the FDA for AMXT 1501 plus DFMO for the treatment of patients with neuroblastoma.